Phone Envelope Map-marker-alt Facebook Twitter Linkedin

Ryan Speer

BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

Trial will be first Phase 3 disease modifying anti-inflammatory insulin sensitizer therapy in Alzheimer’s disease SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) — BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “ Rationale for an Anti-inflammatory …

Read more

Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management

Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021 RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient …

Read more

Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association

NE3107 Featured in the ADA’s Thought Leadership Film Series at Annual Scientific Session SANTA MONICA, Calif., June 29, 2021 (GLOBE NEWSWIRE) — BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the development history …

Read more

BioVie Added to Russell Microcap® Index

SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced has been added as a member of the broad-market Russell Microcap Index, effective after the US …

Read more

BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Chairman Terren Peizer discusses BioVie’s late-stage drug pipeline with multiple shots on goal SANTA MONICA, Calif., June 25, 2021 (GLOBE NEWSWIRE) — BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced an interview with Terren Peizer, Chairman, that will …

Read more

BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced that the first patient has been enrolled in the Company’s Phase 2b trial of BIV201 (continuous …

Read more

Participate in Clinical Research

Volunteer for research studies to learn about your condition, gain access to new treatments and medications, and contribute to medical advancements.

Learn More

Have a Question/Comment?

Biovie Pharma - Transformative Therapies
Facebook-f Twitter Linkedin

Forward Looking Statements

This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.

For Forward Looking Statements, click below:

Click here
Copyright © 2022 BioVie Inc. | ALL RIGHTS RESERVED | Privacy Policy
Website by ImageBloom website design and marketing for clinical research industry